Detalhe da pesquisa
1.
Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.
Blood
; 139(12): 1863-1877, 2022 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34932792
2.
The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.
Br J Haematol
; 175(1): 102-14, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27341313
3.
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma.
Blood Adv
; 3(8): 1230-1243, 2019 04 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-30979721
4.
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis.
Lancet Haematol
; 5(8): e359-e367, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30078408
5.
The DLBCL90 gene-expression assay identifies double-hit lymphomas with high sensitivity in patients from two phase II clinical trials with high-risk diffuse large B-cell lymphoma.
EJHaem
; 2(1): 104-108, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35846101
6.
Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series.
Blood Adv
; 4(9): 1859-1866, 2020 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32374878